OBJECTIVE: To compare the effects of estrogen and estrogen plus progestin on levels of C-reactive protein (CRP) and interleukin-6 (IL-6), and to examine the relationship between these changes and progression of angiographically defined coronary disease. METHODS: Baseline and follow-up (year 1 and year 3) plasma levels of IL-6 and CRP were measured in a subset of 232 patients from the Estrogen Replacement in Atherosclerosis (ERA) trial. RESULTS: Serial angiograms were also available at baseline and closeout. Estrogen alone increased CRP by 40% (P = .01) at 1 year and 38% P = .002) at closeout. Estrogen plus medroxyprogesterone acetate increased CRP by 44.7% P = .001) at 1 year and 54.7% P = .0001) at closeout as compared with baseline levels. There were no significant changes in IL-6 with either treatment. In women in the active treatment arm, change in CRP during the first year was not associated with progression of coronary disease P = .2). CONCLUSIONS:Estrogen and estrogen plus medroxyprogesterone significantly raise CRP levels in women with established coronary disease. In contrast, IL-6 levels are not affected by estrogen or estrogen plus progestin. Estrogen-induced changes in CRP are not associated with progression of atherosclerosis.
RCT Entities:
OBJECTIVE: To compare the effects of estrogen and estrogen plus progestin on levels of C-reactive protein (CRP) and interleukin-6 (IL-6), and to examine the relationship between these changes and progression of angiographically defined coronary disease. METHODS: Baseline and follow-up (year 1 and year 3) plasma levels of IL-6 and CRP were measured in a subset of 232 patients from the Estrogen Replacement in Atherosclerosis (ERA) trial. RESULTS: Serial angiograms were also available at baseline and closeout. Estrogen alone increased CRP by 40% (P = .01) at 1 year and 38% P = .002) at closeout. Estrogen plus medroxyprogesterone acetate increased CRP by 44.7% P = .001) at 1 year and 54.7% P = .0001) at closeout as compared with baseline levels. There were no significant changes in IL-6 with either treatment. In women in the active treatment arm, change in CRP during the first year was not associated with progression of coronary disease P = .2). CONCLUSIONS: Estrogen and estrogen plus medroxyprogesterone significantly raise CRP levels in women with established coronary disease. In contrast, IL-6 levels are not affected by estrogen or estrogen plus progestin. Estrogen-induced changes in CRP are not associated with progression of atherosclerosis.
Authors: B Delia Johnson; Kathleen M Dwyer; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; YuChing Yang; Georgina E Hale; C Noel Bairey Merz Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Amit Khera; Gloria L Vega; Sandeep R Das; Colby Ayers; Darren K McGuire; Scott M Grundy; James A de Lemos Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958
Authors: Stefania Lamon-Fava; David M Herrington; Katalin V Horvath; Ernst J Schaefer; Bela F Asztalos Journal: Metabolism Date: 2010-06-26 Impact factor: 8.694
Authors: Elizabeth A Lawson; Karen K Miller; Vani A Mathur; Madhusmita Misra; Erinne Meenaghan; David B Herzog; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2007-05-22 Impact factor: 5.958
Authors: Shinya Ishii; Arun S Karlamangla; Marcos Bote; Michael R Irwin; David R Jacobs; Hyong Jin Cho; Teresa E Seeman Journal: PLoS One Date: 2012-04-30 Impact factor: 3.240
Authors: Yide Yang; Ming Xie; Shuqian Yuan; Yuan Zeng; Yanhui Dong; Zhenghe Wang; Qiu Xiao; Bin Dong; Jun Ma; Jie Hu Journal: BMC Public Health Date: 2021-06-26 Impact factor: 3.295